Legato Capital Management LLC Has $277,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Legato Capital Management LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 60.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,395 shares of the company’s stock after selling 15,890 shares during the quarter. Legato Capital Management LLC’s holdings in Castle Biosciences were worth $277,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CSTL. R Squared Ltd bought a new stake in shares of Castle Biosciences during the fourth quarter worth $42,000. Quest Partners LLC grew its stake in shares of Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after buying an additional 1,522 shares during the last quarter. US Bancorp DE grew its stake in shares of Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after buying an additional 4,383 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Castle Biosciences during the third quarter worth $140,000. Finally, Assetmark Inc. grew its stake in shares of Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after buying an additional 748 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Performance

Shares of CSTL opened at $27.32 on Friday. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $765.23 million, a P/E ratio of 136.61 and a beta of 0.91. The firm’s fifty day simple moving average is $27.91 and its two-hundred day simple moving average is $29.06. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CSTL. Stephens reaffirmed an “overweight” rating and set a $41.00 target price on shares of Castle Biosciences in a research note on Thursday, January 2nd. Canaccord Genuity Group boosted their price objective on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, October 29th. Lake Street Capital boosted their price objective on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. KeyCorp boosted their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Robert W. Baird boosted their price objective on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Castle Biosciences has a consensus rating of “Buy” and an average target price of $40.29.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $29.14, for a total transaction of $229,244.38. Following the sale, the director now owns 1,425 shares of the company’s stock, valued at approximately $41,524.50. This represents a 84.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Derek J. Maetzold sold 1,972 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $31.35, for a total transaction of $61,822.20. Following the sale, the insider now directly owns 85,748 shares in the company, valued at $2,688,199.80. This trade represents a 2.25 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,771 shares of company stock valued at $886,112. 7.20% of the stock is currently owned by insiders.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.